A broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis.

Post-exposure prophylaxis (PEP) is highly effective in preventing disease progression of rabies when used in timely and appropriate manner. The key treatment for PEP is infiltration of rabies immune globulin (RIG) into lesion site after bite exposure, besides wound care and vaccination. Unfortunatel...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pan Kyeom Kim, Jung Sun Ahn, Cheol Min Kim, Ji Min Seo, Sun Ju Keum, Hyun Joo Lee, Min Joo Choo, Min Soo Kim, Jun Young Lee, Ki Eun Maeng, Ji Young Shin, Kye Sook Yi, Modupe O V Osinubi, Richard Franka, Lauren Greenberg, Madhusudana Shampur, Charles E Rupprecht, Soo Young Lee
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/146742a2ffc6488a908543af9a327637
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:146742a2ffc6488a908543af9a327637
record_format	dspace
spelling	oai:doaj.org-article:146742a2ffc6488a908543af9a3276372021-12-02T20:08:41ZA broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis.1932-620310.1371/journal.pone.0256779https://doaj.org/article/146742a2ffc6488a908543af9a3276372021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0256779https://doaj.org/toc/1932-6203Post-exposure prophylaxis (PEP) is highly effective in preventing disease progression of rabies when used in timely and appropriate manner. The key treatment for PEP is infiltration of rabies immune globulin (RIG) into lesion site after bite exposure, besides wound care and vaccination. Unfortunately, however, RIG is expensive and its supply is limited. Currently, several anti-rabies virus monoclonal antibody (mAb) products are under development as alternatives to RIG, and two recently received regulatory approval in India. In this study, fully human mAbs that recognize different rabies virus glycoprotein conformational antigenic site (II and III) were created from peripheral blood mononuclear cells of heathy vaccinated subjects. These mAbs neutralized a diverse range of lyssavirus types. As at least two anti-rabies virus mAbs are recommended for use in human PEP to ensure broad coverage against diverse lyssaviruses and to minimize possible escape variants, two most potent mAbs, NP-19-9 and 11B6, were selected to be used as cocktail treatment. These two mAbs were broadly reactive to different types of lyssaviruses isolates, and were shown to have no interference with each other. These results suggest that NP-19-9 and 11B6 are potent candidates to be used for PEP, suggesting further studies involving clinical studies in human.Pan Kyeom KimJung Sun AhnCheol Min KimJi Min SeoSun Ju KeumHyun Joo LeeMin Joo ChooMin Soo KimJun Young LeeKi Eun MaengJi Young ShinKye Sook YiModupe O V OsinubiRichard FrankaLauren GreenbergMadhusudana ShampurCharles E RupprechtSoo Young LeePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 9, p e0256779 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Pan Kyeom Kim Jung Sun Ahn Cheol Min Kim Ji Min Seo Sun Ju Keum Hyun Joo Lee Min Joo Choo Min Soo Kim Jun Young Lee Ki Eun Maeng Ji Young Shin Kye Sook Yi Modupe O V Osinubi Richard Franka Lauren Greenberg Madhusudana Shampur Charles E Rupprecht Soo Young Lee A broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis.
description	Post-exposure prophylaxis (PEP) is highly effective in preventing disease progression of rabies when used in timely and appropriate manner. The key treatment for PEP is infiltration of rabies immune globulin (RIG) into lesion site after bite exposure, besides wound care and vaccination. Unfortunately, however, RIG is expensive and its supply is limited. Currently, several anti-rabies virus monoclonal antibody (mAb) products are under development as alternatives to RIG, and two recently received regulatory approval in India. In this study, fully human mAbs that recognize different rabies virus glycoprotein conformational antigenic site (II and III) were created from peripheral blood mononuclear cells of heathy vaccinated subjects. These mAbs neutralized a diverse range of lyssavirus types. As at least two anti-rabies virus mAbs are recommended for use in human PEP to ensure broad coverage against diverse lyssaviruses and to minimize possible escape variants, two most potent mAbs, NP-19-9 and 11B6, were selected to be used as cocktail treatment. These two mAbs were broadly reactive to different types of lyssaviruses isolates, and were shown to have no interference with each other. These results suggest that NP-19-9 and 11B6 are potent candidates to be used for PEP, suggesting further studies involving clinical studies in human.
format	article
author	Pan Kyeom Kim Jung Sun Ahn Cheol Min Kim Ji Min Seo Sun Ju Keum Hyun Joo Lee Min Joo Choo Min Soo Kim Jun Young Lee Ki Eun Maeng Ji Young Shin Kye Sook Yi Modupe O V Osinubi Richard Franka Lauren Greenberg Madhusudana Shampur Charles E Rupprecht Soo Young Lee
author_facet	Pan Kyeom Kim Jung Sun Ahn Cheol Min Kim Ji Min Seo Sun Ju Keum Hyun Joo Lee Min Joo Choo Min Soo Kim Jun Young Lee Ki Eun Maeng Ji Young Shin Kye Sook Yi Modupe O V Osinubi Richard Franka Lauren Greenberg Madhusudana Shampur Charles E Rupprecht Soo Young Lee
author_sort	Pan Kyeom Kim
title	A broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis.
title_short	A broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis.
title_full	A broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis.
title_fullStr	A broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis.
title_full_unstemmed	A broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis.
title_sort	broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/146742a2ffc6488a908543af9a327637
work_keys_str_mv	AT pankyeomkim abroadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT jungsunahn abroadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT cheolminkim abroadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT jiminseo abroadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT sunjukeum abroadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT hyunjoolee abroadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT minjoochoo abroadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT minsookim abroadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT junyounglee abroadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT kieunmaeng abroadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT jiyoungshin abroadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT kyesookyi abroadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT modupeovosinubi abroadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT richardfranka abroadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT laurengreenberg abroadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT madhusudanashampur abroadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT charleserupprecht abroadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT sooyounglee abroadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT pankyeomkim broadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT jungsunahn broadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT cheolminkim broadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT jiminseo broadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT sunjukeum broadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT hyunjoolee broadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT minjoochoo broadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT minsookim broadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT junyounglee broadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT kieunmaeng broadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT jiyoungshin broadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT kyesookyi broadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT modupeovosinubi broadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT richardfranka broadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT laurengreenberg broadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT madhusudanashampur broadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT charleserupprecht broadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis AT sooyounglee broadspectrumandhighlypotenthumanmonoclonalantibodycocktailforrabiesprophylaxis
_version_	1718375165704798208

A broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis.

Ejemplares similares